Cureus review offers framework for insulin deintensification after GLP-1 therapy
The paper collects evidence on reducing insulin in type 2 diabetes patients started on incretin-based treatment and proposes a practical clinical approach.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 7 23:55 ETSource: Cureus
The wire
- 01A Cureus review covers evidence and a proposed clinical framework for deintensifying insulin in people with type 2 diabetes after starting GLP-1-based therapy.
- 02Clinicians managing patients on both insulin and incretin drugs face hypoglycemia risk and unclear tapering guidance; a structured framework addresses a common prescribing question.
- 03This is a narrative review rather than new trial data, and only the title and abstract heading are available; readers should check the full text for the strength of the underlying evidence.
From the source
Read at cureus.comInsulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework
